These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27238300)

  • 1. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.
    Saeed H; Hnoosh D; Huang B; Durbin EB; McGrath PC; Desimone P; Maynard E; Anthony LB; Dineen SP; Hosein PJ; Tzeng CW
    J Surg Oncol; 2016 Sep; 114(4):451-5. PubMed ID: 27238300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy.
    Newhook TE; Prakash LR; Soliz J; Hancher-Hodges S; Speer BB; Wilks JA; Bruno ML; Dewhurst WL; Arvide EM; Maxwell JE; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
    J Surg Oncol; 2021 Dec; 124(8):1381-1389. PubMed ID: 34398988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resected pancreatic adenocarcinoma: An Asian institution's experience.
    Ng KYY; Chow EWX; Jiang B; Lim C; Goh BKP; Lee SY; Teo JY; Tan DMY; Cheow PC; Ooi LLPJ; Chow PKH; Lee JJX; Kam JH; Koh YX; Jeyaraj PR; Tan EK; Choo SP; Chan CY; Chung AYF; Tai D
    Cancer Rep (Hoboken); 2021 Oct; 4(5):e1393. PubMed ID: 33939335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal timing and treatment strategy for pancreatic cancer.
    Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
    J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
    Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
    Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer.
    Le AT; Huang B; Hnoosh D; Saeed H; Dineen SP; Hosein PJ; Durbin EB; Kudrimoti M; McGrath PC; Tzeng CD
    J Surg Res; 2017 Jun; 214():1-8. PubMed ID: 28624029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.
    Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R
    Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
    Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
    J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?
    Bertens KA; Massman JD; Helton S; Garbus S; Mandelson MM; Lin B; Picozzi VJ; Biehl T; Alseidi AA; Rocha FG
    J Surg Oncol; 2018 Jun; 117(8):1655-1663. PubMed ID: 29761510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
    Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
    Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
    Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.
    Lee W; Yoon YS; Han HS; Jang JY; Cho JY; Jung W; Kwon W; Choi Y; Kim SW
    World J Surg; 2017 Feb; 41(2):562-573. PubMed ID: 27834017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.
    Kagedan DJ; Raju RS; Dixon ME; Shin E; Li Q; Liu N; Elmi M; El-Sedfy A; Paszat L; Kiss A; Earle CC; Mittmann N; Coburn NG
    HPB (Oxford); 2016 Apr; 18(4):339-47. PubMed ID: 27037203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of chemotherapy sequencing on resectable pancreatic cancer by stage.
    Vega EA; Kutlu OC; Salehi O; Alarcon SV; Abudalou M; Kozyreva O; Krishnan S; Lee D; Freeman R; Conrad C
    Surg Oncol; 2022 Mar; 40():101694. PubMed ID: 34973593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Groot VP; Gemenetzis G; Blair AB; Rivero-Soto RJ; Yu J; Javed AA; Burkhart RA; Rinkes IHMB; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
    Ann Surg; 2019 Jun; 269(6):1154-1162. PubMed ID: 31082915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer.
    Gruhl JD; Garrido-Laguna I; Francis SR; Affolter K; Tao R; Lloyd S
    Cancer Med; 2020 Mar; 9(5):1703-1711. PubMed ID: 31945808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.